Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST) Meeting Abstract
| Authors: | Tap, W. D.; Somaiah, N.; Kang, Y. K.; Ryan, A.; Razak, A.; Garrido, M.; Desar, I. M. E.; Italiano, A.; Reichardt, P.; Wilky, B. A.; Heinrich, M. C.; Druta, M.; Singh, A. S.; Attia, S.; Bauer, S.; Serrano, C.; Moynihan, K.; Lawrence, J.; Wagner, A. J.; Trent, J. C. |
| Abstract Title: | Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406051 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS11588 |
| Notes: | Meeting Abstract: TPS11588 -- Source: Wos |
